Radioligand therapy of metastatic prostate cancer using 177Lu- PSMA-617 after radiation exposure to 223Ra-dichloride

Oncotarget

Volumn 8, Issue 33, 2017, Pages 55567-55574

  Ahmadzadehfar, Hojjat ^a   Zimbelmann, Stefanie ^a   Yordanova, Anna ^a   Fimmers, Rolf ^b   Kürpig, Stefan ^a   Eppard, Elisabeth ^a   Gaertner, Florian C ^a   Wei, Xiao ^a   Hauser, Stefan ^a   Essler, Markus ^a  

^a UNIVERSITY HOSPITAL BONN   (Germany)

^b UNIVERSITY OF BONN   (Germany)

Author keywords

Hematotoxicity; Lu PSMA 617; Prostate cancer; Radioligand therapy; Radium 223

Indexed keywords

DICHLORIDE RA 223; HEMOGLOBIN; PROSTATE SPECIFIC ANTIGEN; PROSTATE SPECIFIC MEMBRANE ANTIGEN 617 LU 177; RADIOPHARMACEUTICAL AGENT; UNCLASSIFIED DRUG;

ADULT; AGED; ANEMIA; ARTICLE; BLOOD TOXICITY; BONE METASTASIS; CANCER RADIOTHERAPY; CLINICAL ARTICLE; CONTROLLED STUDY; DISTANT METASTASIS; DRUG SAFETY; HEMOGLOBIN BLOOD LEVEL; HUMAN; LEUKOCYTE COUNT; LEUKOPENIA; MALE; MEDICAL HISTORY; MULTIPLE CYCLE TREATMENT; PROSTATE CANCER; RADIATION EXPOSURE; RADIATION SAFETY; RETROSPECTIVE STUDY; THROMBOCYTE COUNT; THROMBOCYTOPENIA; TREATMENT RESPONSE;

EID: 85023601403     PISSN: None     EISSN: 19492553     Source Type: Journal    
DOI: 10.18632/oncotarget.15698     Document Type: Article

References (35)

1. Afshar-Oromieh A, Hetzheim H, Kratochwil C, Benesova M, Eder M, Neels OC, Eisenhut M, Kubler W, Holland-Letz T, Giesel FL, Mier W, Kopka K, Haberkorn U. The Theranostic PSMA Ligand PSMA-617 in the Diagnosis of Prostate Cancer by PET/CT: Biodistribution in Humans, Radiation Dosimetry, and First Evaluation of Tumor Lesions. J Nucl Med. 2015; 56: 1697-705. doi: 10.2967/jnumed.115.161299
2. Afshar-Oromieh A, Malcher A, Eder M, Eisenhut M, Linhart HG, Hadaschik BA, Holland-Letz T, Giesel FL, Kratochwil C, Haufe S, Haberkorn U, Zechmann CM. PET imaging with a [68Ga]gallium-labelled PSMA ligand for the diagnosis of prostate cancer: biodistribution in humans and first evaluation of tumour lesions. Eur J Nucl Med Mol Imaging. 2013; 40: 486-95. doi: 10.1007/s00259-012-2298-2
3. Rai BP, Baum RP, Patel A, Hughes R, Alonzi R, Lane T, Adshead J, Vasdev N. The Role of Positron Emission Tomography With (68)Gallium (Ga)-Labeled Prostatespecific Membrane Antigen (PSMA) in the Management of Patients With Organ-confined and Locally Advanced Prostate Cancer Prior to Radical Treatment and After Radical Prostatectomy. Urology. 2016; 95: 11-5. doi: 10.1016/j.urology.2015.12.048
4. Ahmadzadehfar H, Azgomi K, Hauser S, Wei X, Yordanova A, Gaertner F, Kurpig S, Strunk H, Essler M. 68Ga-PSMA-11 PET as a gate-keeper for the treatment of metastatic prostate cancer with radium-223: proof of concept. J Nucl Med. 2016. doi: 10.2967/jnumed.116.178533
5. Ahmadzadehfar H, Rahbar K, Kurpig S, Bogemann M, Claesener M, Eppard E, Gartner F, Rogenhofer S, Schafers M, Essler M. Early side effects and first results of radioligand therapy with (177)Lu-DKFZ-617 PSMA of castrate-resistant metastatic prostate cancer: a two-centre study. EJNMMI Res. 2015; 5: 114. doi: 10.1186/s13550-015-0114-2
6. Baum RP, Kulkarni HR, Schuchardt C, Singh A, Wirtz M, Wiessalla S, Schottelius M, Mueller D, Klette I, Wester HJ. 177Lu-Labeled Prostate-Specific Membrane Antigen Radioligand Therapy of Metastatic Castration-Resistant Prostate Cancer: Safety and Efficacy. J Nucl Med. 2016; 57: 1006-13. doi: 10.2967/jnumed.115.168443
7. Ahmadzadehfar H, Eppard E, Kurpig S, Fimmers R, Yordanova A, SchlenkhoffCD, Gartner F, Rogenhofer S, Essler M. Therapeutic response and side effects of repeated radioligand therapy with 177Lu-PSMA-DKFZ-617 of castrate-resistant metastatic prostate cancer. Oncotarget. 2016; 7: 12477-88. doi: 10.18632/oncotarget.7245
8. Rahbar K, Ahmadzadehfar H, Kratochwil C, Haberkorn U, Schafers M, Essler M, Baum RP, Kulkarni HR, Schmidt M, Drzezga A, Bartenstein P, PfestroffA, Luster M, et al. German Multicenter Study Investigating 177Lu-PSMA-617 Radioligand Therapy in Advanced Prostate Cancer Patients. J Nucl Med. 2017; 58: 85-90. doi: 10.2967/jnumed.116.183194
9. Cornford P, Bellmunt J, Bolla M, Briers E, De Santis M, Gross T, Henry AM, Joniau S, Lam TB, Mason MD, van der Poel HG, van der Kwast TH, Rouviere O, et al. EAU-ESTRO-SIOG Guidelines on Prostate Cancer. Part II: Treatment of Relapsing, Metastatic, and Castration-Resistant Prostate Cancer. Eur Urol. 2016. doi: 10.1016/j. eururo.2016.08.002
10. Rahbar K, Schmidt M, Heinzel A, Eppard E, Bode A, Yordanova A, Claesener M, Ahmadzadehfar H. Response and Tolerability of a Single Dose of 177Lu-PSMA-617 in Patients with Metastatic Castration-Resistant Prostate Cancer: A Multicenter Retrospective Analysis. J Nucl Med. 2016; 57: 1334-8. doi: 10.2967/jnumed.116.173757
11. SchlenkhoffCD, Gaertner F, Essler M, Schmidt M, Ahmadzadehfar H. Positive Influence of 177Lu PSMA-617 Therapy on Bone Marrow Depression Caused by Metastatic Prostate Cancer. Clin Nucl Med. 2016; 41: 478-80. doi: 10.1097/RLU.0000000000001195
12. Scher HI, Fizazi K, Saad F, Taplin ME, Sternberg CN, Miller K, de Wit R, Mulders P, Chi KN, Shore ND, Armstrong AJ, Flaig TW, Flechon A, et al. Increased survival with enzalutamide in prostate cancer after chemotherapy. N Engl J Med. 2012; 367: 1187-97. doi: 10.1056/NEJMoa1207506
13. Ryan CJ, Smith MR, Fizazi K, Saad F, Mulders PF, Sternberg CN, Miller K, Logothetis CJ, Shore ND, Small EJ, Carles J, Flaig TW, Taplin ME, et al. Abiraterone acetate plus prednisone versus placebo plus prednisone in chemotherapy-naive men with metastatic castrationresistant prostate cancer (COU-AA-302): final overall survival analysis of a randomised, double-blind, placebocontrolled phase 3 study. Lancet Oncol. 2015; 16: 152-60. doi: 10.1016/S1470-2045(14)71205-7
14. Parker C, Nilsson S, Heinrich D, Helle SI, O'Sullivan JM, Fossa SD, Chodacki A, Wiechno P, Logue J, Seke M, Widmark A, Johannessen DC, Hoskin P, et al. Alpha emitter radium-223 and survival in metastatic prostate cancer. N Engl J Med. 2013; 369: 213-23. doi: 10.1056/NEJMoa1213755
15. de Bono JS, Oudard S, Ozguroglu M, Hansen S, Machiels JP, Kocak I, Gravis G, Bodrogi I, Mackenzie MJ, Shen L, Roessner M, Gupta S, Sartor AO. Prednisone plus cabazitaxel or mitoxantrone for metastatic castrationresistant prostate cancer progressing after docetaxel treatment: a randomised open-label trial. Lancet. 2010; 376: 1147-54. doi: 10.1016/S0140-6736(10)61389-X
16. KantoffPW, Higano CS, Small EJ, Whitmore JB, Frohlich MW, Schellhammer PF. Re: interdisciplinary critique of sipuleucel-T as immunotherapy in castration-resistant prostate cancer. J Natl Cancer Inst. 2012; 104: 1107-9; author reply 9-12. doi: 10.1093/jnci/djs279
17. Petrylak DP, Tangen CM, Hussain MH, Lara PN, Jr., Jones JA, Taplin ME, Burch PA, Berry D, Moinpour C, Kohli M, Benson MC, Small EJ, Raghavan D, et al. Docetaxel and estramustine compared with mitoxantrone and prednisone for advanced refractory prostate cancer. N Engl J Med. 2004; 351: 1513-20. doi: 10.1056/NEJMoa041318
18. Hoskin P, Sartor O, O'Sullivan JM, Johannessen DC, Helle SI, Logue J, Bottomley D, Nilsson S, Vogelzang NJ, Fang F, Wahba M, Aksnes AK, Parker C. Efficacy and safety of radium-223 dichloride in patients with castration-resistant prostate cancer and symptomatic bone metastases, with or without previous docetaxel use: a prespecified subgroup analysis from the randomised, double-blind, phase 3 ALSYMPCA trial. Lancet Oncol. 2014; 15: 1397-406. doi: S1470-2045(14)70474-7
19. Nilsson S, Franzen L, Parker C, Tyrrell C, Blom R, Tennvall J, Lennernas B, Petersson U, Johannessen DC, Sokal M, Pigott K, Yachnin J, Garkavij M, et al. Bonetargeted radium-223 in symptomatic, hormone-refractory prostate cancer: a randomised, multicentre, placebocontrolled phase II study. Lancet Oncol. 2007; 8: 587-94. doi: S1470-2045(07)70147-X
20. Parker C, Sartor O. Radium-223 in prostate cancer. N Engl J Med. 2013; 369: 1659-60. doi: 10.1056/NEJMc1310231
21. Sartor O, Coleman R, Nilsson S, Heinrich D, Helle SI, O'Sullivan JM, Fossa SD, Chodacki A, Wiechno P, Logue J, Widmark A, Johannessen DC, Hoskin P, et al. Effect of radium-223 dichloride on symptomatic skeletal events in patients with castration-resistant prostate cancer and bone metastases: results from a phase 3, double-blind, randomised trial. Lancet Oncol. 2014; 15: 738-46. doi: S1470-2045(14)70183-4
22. Ahmadzadehfar H, SchlenkhoffCD, Rogenhofer S, Yordanova A, Essler M. 68Ga-PSMA-11 PET Represents the Tumoricidal Effect of 223Ra in a Patient With Castrate-Resistant Metastatic Prostate Cancer. Clin Nucl Med. 2016; 41: 695-6. doi: 10.1097/RLU.0000000000001286
23. Rahbar K, Bode A, Weckesser M, Avramovic N, Claesener M, Stegger L, Bogemann M. Radioligand Therapy With 177Lu-PSMA-617 as A Novel Therapeutic Option in Patients With Metastatic Castration Resistant Prostate Cancer. Clin Nucl Med. 2016; 41: 522-8. doi: 10.1097/RLU.0000000000001240
24. Kratochwil C, Giesel FL, Stefanova M, Benesova M, Bronzel M, Afshar-Oromieh A, Mier W, Eder M, Kopka K, Haberkorn U. PSMA-Targeted Radionuclide Therapy of Metastatic Castration-Resistant Prostate Cancer with 177Lu-Labeled PSMA-617. J Nucl Med. 2016; 57: 1170-6. doi: 10.2967/jnumed.115.171397
25. Khafagy R, Shackley D, Samuel J, O'Flynn K, Betts C, Clarke N. Complications arising in the final year of life in men dying from advanced prostate cancer. J Palliat Med. 2007; 10: 705-11. doi: 10.1089/jpm.2006.0185
26. Nalesnik JG, Mysliwiec AG, Canby-Hagino E. Anemia in men with advanced prostate cancer: incidence, etiology, and treatment. Rev Urol. 2004; 6: 1-4
27. Strum SB, McDermed JE, Scholz MC, Johnson H, Tisman G. Anaemia associated with androgen deprivation in patients with prostate cancer receiving combined hormone blockade. Br J Urol. 1997; 79: 933-41
28. Nieder C, Haukland E, Pawinski A, Dalhaug A. Anaemia and thrombocytopenia in patients with prostate cancer and bone metastases. BMC Cancer. 2010; 10: 284. doi: 10.1186/1471-2407-10-284
29. Tu SM, Kim J, Pagliaro LC, Vakar-Lopez F, Wong FC, Wen S, General R, PodoloffDA, Lin SH, Logothetis CJ. Therapy tolerance in selected patients with androgenindependent prostate cancer following strontium-89 combined with chemotherapy. J Clin Oncol. 2005; 23: 7904-10. doi: 10.1200/JCO.2005.01.2310
30. Miederer M, Thomas C, Beck J, Hampel C, Krieger C, Baque PE, Helisch A, Schreckenberger M. Haematopoietic toxicity of radium-223 in patients with high skeletal tumour burden. Nuklearmedizin. 2015; 54: 197-203. doi: 10.3413/Nukmed-0751-15-06
31. Etchebehere EC, Araujo JC, Fox PS, Swanston NM, Macapinlac HA, Rohren EM. Prognostic Factors in Patients Treated with 223Ra: The Role of Skeletal Tumor Burden on Baseline 18F-Fluoride PET/CT in Predicting Overall Survival. J Nucl Med. 2015; 56: 1177-84. doi: 10.2967/jnumed.115.158626
32. Etchebehere EC, Araujo JC, Milton DR, Erwin WD, Wendt RE, 3rd, Swanston NM, Fox P, Macapinlac HA, Rohren EM. Skeletal Tumor Burden on Baseline 18F-Fluoride PET/CT Predicts Bone Marrow Failure After 223Ra Therapy. Clin Nucl Med. 2016; 41: 268-73. doi: 10.1097/RLU.0000000000001118
33. Vogelzang NJ, Coleman RE, Michalski JM, Nilsson S, O'Sullivan JM, Parker C, Widmark A, Thuresson M, Xu L, Germino J, Sartor O. Hematologic Safety of Radium-223 Dichloride: Baseline Prognostic Factors Associated With Myelosuppression in the ALSYMPCA Trial. Clin Genitourin Cancer. 2017; 15: 42-52 e8. doi: 10.1016/j. clgc.2016.07.027
34. Ferdinandus J, Eppard E, Gaertner FC, Kurpig S, Fimmers R, Yordanova A, Hauser S, Feldmann G, Essler M, Ahmadzadehfar H. Predictors of Response to Radioligand Therapy of Metastatic Castrate-Resistant Prostate Cancer with 177Lu-PSMA-617. J Nucl Med. 2017; 58: 312-9. doi: 10.2967/jnumed.116.178228
35. (2013). National Cancer Institute Guidelines For Investigators: Adverse event reporting requirements for DCTC DCTD (CTEP and CIP) and DCP INDs and IDEs